Atherosclerosis
Volume 193, Issue 2 , Pages 343-351 , August 2007

The different effect of pioglitazone as compared to insulin on expression of hepatic and intestinal genes regulating post-prandial lipoproteins in diabetes

  • S. Lally
    • ,
  • D. Owens
    • ,
  • G.H. Tomkin

      Affiliations

    • Corresponding Author InformationCorresponding author at: Diabetes Research Foundation, Clontra, Quinns Road, Shankill, Co Dublin, Ireland. Tel.: +353 1 2390658; fax: +353 1 2721395.

Received 16 May 2006 ,Revised 30 August 2006 ,Accepted 27 September 2006.

References 

  1. Tanaka A. Postprandial hyperlipidemia and atherosclerosis. J Atheroscler Thromb. 2004;11:322–329
  2. Botham KM, Bravo E, Elliott J, Wheeler-Jones CP. Direct interaction of dietary lipids carried in chylomicron remnants with cells of the artery wall: implications for atherosclerosis development. Curr Pharm Des. 2005;11:3681–3695
  3. Curtin A, Deegan P, Owens D, et al. Alterations in apolipoprotein B48 in the postprandial state. Diabetologia. 1994;37:1259–1262
  4. Phillips C, Mullan K, Owens D, Tomkin GH. Intestinal microsomal triglyceride transfer protein in type 2 diabetic and non-diabetic subjects: the relationship to triglyceride-rich postprandial lipoprotein composition. Atherosclerosis. 2006;187:57–64
  5. Lally S, Tan CY, Owens D, Tomkin GH. Messenger RNA levels of genes involved in dysregulation of postprandial lipoproteins in type 2 diabetes: the role of Niemann Pick C1-like 1, ATP binding cassette transporters ABCG5 and G8 and microsomal triglyceride transfer protein. Diabetologia. 2006;49:1008–1016
  6. Gylling H, Miettinen TA. Cholesterol absorption, synthesis and LDL metabolism in NIDDM. Diabetes Care. 1997;20:90–95
  7. Gleeson A, Owens D, Collins P, Johnson , Tomkin GH. The relationship between cholesterol absorption and intestinal cholesterol synthesis in the diabetic rat model. Int J Exp Diab Res. 2000;1:203–210
  8. Altmann SW, Davis HR, Zhu LJ, et al. Niemann-Pick C1 like 1 protein is critical for intestinal cholesterol absorption. Science. 2004;303:1201–1204
  9. Berge KE, Tian H, Graf GA, et al. Accumulation of dietary cholesterol in sitosterolemia caused by mutations in adjacent ABC transporters. Science. 2000;290:1771–1775
  10. Yki-Jarvinen H. Drug therapy thiazolininediones. N Engl J Med. 2004;351:1106–1119
  11. Schoonjans K, Staels B, Auwerx J. The peroxisome proliferator activated receptors (PPARS) and their effects on lipid metabolism and adipocyte differentiation. Biochim Biophys Acta. 1996;1302:93–109
  12. Dormandy JA, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective Pioglitazone Clinical Trial in Macrovascular Events): a randomised controlled trial. Lancet. 2005;366:1279–1289
  13. Gaede P, Parving HH, Pedersen O. ProActive study. Lancet. 2006;367:23–24
  14. Phillips C, Murugasu G, Owens D, et al. Improved metabolic control reduces the number of postprandial apolipoprotein B48-containing particles in Type 2 diabetes. Atherosclerosis. 2000;148:283–291
  15. Annuzzi G, De Natale C, Iovine C, et al. Insulin resistance is independently associated with postprandial alterations of triglyceride-rich lipoproteins in type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol. 2004;24:2397–2402
  16. Goldberg RB, et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care. 2005;22:1547–1554
  17. Lewis GF, Uffelman K, Naples M, et al. Intestinal lipoprotein overproduction, a newly recognized component of insulin resistance, is ameliorated by the insulin sensitizer rosiglitazone: studies in the fructose-fed Syrian Golden hamster. Endocrinology. 2005;146:247–255
  18. O’Meara N, Devery R, Owens D, et al. Serum lipoproteins and cholesterol metabolism in two hypercholesterolaemic rabbit models. Diabetologia. 1991;34:139–143
  19. O’Meara N, Devery R, Owens D, et al. Cholesterol metabolism in the alloxan-induced diabetic rabbit. Diabetes. 1990;39:626–633
  20. Feingold KR, Wilson DE, Wood LC, et al. Diabetes increases hepatic hydroxymethyl glutaryl coenzyme A reductase protein and mRNA levels in the small intestine. Metabolism. 1994;43:450–454
  21. Wetterau JR, Aggerbeck LP, Bouma ME, et al. Absence of microsomal triglyceride transfer protein in individuals with abetalipoproteinemia. Science. 1992;258:999–1001
  22. Gleeson A, Anderton K, Owens D, et al. The role of microsomal triglyceride transfer protein and dietary cholesterol in chylomicron production in diabetes. Diabetologia. 1999;42:944–949
  23. Phillips C, Owens D, Collins P, Tomkin GH. Microsomal triglyceride transfer protein: does insulin resistance play a role in the regulation of chylomicron assembly?. Atherosclerosis. 2002;160:355–360
  24. HagenDL , Kienzle B, Jamil H, Hariharan N. Transcriptional regulation of human and hamster microsomal triglyceride transfer protein genes. Cell type-specific expression and response to metabolic regulators. J Biol Chem. 1994;269:28737–28744
  25. Lin MC, Gordon D, Wetterau JR. Microsomal triglyceride transfer protein (MTTP) regulation in HepG2 cells: insulin negatively regulates MTTP gene expression. J Lipid Res. 1995;36:1073–1081
  26. Phillips C, Anderton K, Bennett A, et al. Intestinal rather than hepatic microsomal triglyceride transfer protein as a cause of postprandial dyslipidaemia in diabetes. Metabolism. 2002;51:847–852
  27. van der Veen JN, Kruit JK, Havinga R, et al. Reduced cholesterol absorption upon PPARdelta activation coincides with decreased intestinal expression of NPC1L1. J Lipid Res. 2005;46:526–534
  28. Graf GA, Yu L, Li WP, et al. ABCG5 and ABCG8 are obligate heterodimers for protein trafficking and biliary excretion. J Biol Chem. 2003;278:48275–48282
  29. Yu L, Gupta S, Xu F, et al. Expression of ABCG5 and ABCG8 is required for regulation of biliary cholesterol secretion. J Biol Chem. 2005;280:8742–8747
  30. Bloks VW, Bakker-Van Waarde WM, Verkade HJ, et al. Down-regulation of hepatic and intestinal Abcg5 and Abcg8 expression associated with altered sterol fluxes in rats with streptozotocin-induced diabetes. Diabetologia. 2004;47:104–112
  31. van Heek M, Farley C, Compton DS, et al. Ezetimibe potently inhibits cholesterol absorption but does not affect acute hepatic or intestinal cholesterol synthesis in rats. Br J Pharmacol. 2003;138:1459–1464
  32. Repa J, Turley S, Quan G, Dietchy J. Dillineation of molecular changes in intrahepatic cholestesterol metabolism resulting from diminished cholesterol absorption. J Lipid Res. 2005;46:779–789
  33. Staels B, Fruchart J-C. Therapeutic roles of peroxisome proliferators-activated receptor agonists. Diabetes. 2005;54:2460–2470
  34. Raz I, Eldor R, Cernea S, Shafrir E. Diabetes: mellitus or lipidus?. Diabetologia. 2003;46:433–440

PII: S0021-9150(06)00590-9

doi: 10.1016/j.atherosclerosis.2006.09.031

Atherosclerosis
Volume 193, Issue 2 , Pages 343-351 , August 2007

Article Tools

* Image Usage & Resolution